Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.
Cao Y, Yang G, Hunter ZR, Liu X, Xu L, Chen J, Tsakmaklis N, Hatjiharissi E, Kanan S, Davids MS, Castillo JJ, Treon SP. Cao Y, et al. Among authors: tsakmaklis n. Br J Haematol. 2015 Jul;170(1):134-8. doi: 10.1111/bjh.13278. Epub 2015 Jan 12. Br J Haematol. 2015. PMID: 25582069 Free article. No abstract available.
Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia.
Jiménez C, Chan GG, Xu L, Tsakmaklis N, Kofides A, Demos MG, Chen J, Liu X, Munshi M, Yang G, Castillo JJ, Wiestner A, García-Sanz R, Treon SP, Hunter ZR. Jiménez C, et al. Among authors: tsakmaklis n. Br J Haematol. 2020 Jun;189(6):1165-1170. doi: 10.1111/bjh.16463. Epub 2020 Feb 27. Br J Haematol. 2020. PMID: 32103491 Free PMC article. Clinical Trial.
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib.
Castillo JJ, Abeykoon JP, Gustine JN, Zanwar S, Mein K, Flynn CA, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, King R, Yang G, Hunter ZR, Advani RH, Palomba ML, Ansell SM, Gertz MA, Kapoor P, Treon SP. Castillo JJ, et al. Among authors: tsakmaklis n. Br J Haematol. 2021 Feb;192(3):542-550. doi: 10.1111/bjh.17225. Epub 2020 Nov 18. Br J Haematol. 2021. PMID: 33207010 Free PMC article. Clinical Trial.
CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.
Vos JM, Tsakmaklis N, Patterson CJ, Meid K, Castillo JJ, Brodsky P, Ganz T, Pals ST, Kersten MJ, Xu L, Yang G, Treon SP, Hunter ZR. Vos JM, et al. Among authors: tsakmaklis n. Haematologica. 2017 Nov;102(11):e452-e455. doi: 10.3324/haematol.2017.172627. Epub 2017 Aug 10. Haematologica. 2017. PMID: 28798070 Free PMC article. No abstract available.
MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4.
Guerrera ML, Tsakmaklis N, Xu L, Yang G, Demos M, Kofides A, Chan GG, Manning RJ, Liu X, Chen JG, Munshi M, Patterson CJ, Castillo JJ, Dubeau T, Gustine J, Carrasco RD, Arcaini L, Varettoni M, Cazzola M, Treon SP, Hunter ZR. Guerrera ML, et al. Among authors: tsakmaklis n. Haematologica. 2018 Sep;103(9):e408-e411. doi: 10.3324/haematol.2018.190181. Epub 2018 Mar 29. Haematologica. 2018. PMID: 29599202 Free PMC article. No abstract available.
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.
Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Kofides A, Jimenez C, Chan GG, Chen J, Liu X, Munshi M, Gustine J, Meid K, Patterson CJ, Yang G, Dubeau T, Samur MK, Castillo JJ, Anderson KC, Munshi NC, Treon SP. Hunter ZR, et al. Among authors: tsakmaklis n. Blood Adv. 2018 Nov 13;2(21):2937-2946. doi: 10.1182/bloodadvances.2018022962. Blood Adv. 2018. PMID: 30401751 Free PMC article.
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas.
Liu X, Chen JG, Munshi M, Hunter ZR, Xu L, Kofides A, Tsakmaklis N, Demos MG, Guerrera ML, Chan GG, Jimenez C, Patterson CJ, Meid K, Keezer A, Castillo JJ, Treon SP, Yang G. Liu X, et al. Among authors: tsakmaklis n. Blood Adv. 2020 Jan 14;4(1):141-153. doi: 10.1182/bloodadvances.2019000947. Blood Adv. 2020. PMID: 31935288 Free PMC article.
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.
Munshi M, Liu X, Chen JG, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Jimenez C, Chan GG, Hunter ZR, Palomba ML, Argyropoulos KV, Meid K, Keezer A, Gustine J, Dubeau T, Castillo JJ, Patterson CJ, Wang J, Buhrlage SJ, Gray NS, Treon SP, Yang G. Munshi M, et al. Among authors: tsakmaklis n. Blood Cancer J. 2020 Jan 31;10(1):12. doi: 10.1038/s41408-020-0277-6. Blood Cancer J. 2020. PMID: 32005797 Free PMC article.
41 results